Prostate cancer is one of the most commonly diagnosed cancers in men in the United States and a major cause of cancer morbidity and mortality. Throughout its history, the Johns Hopkins Prostate Cancer SPORE has focused on reducing prostate cancer incidence and mortality by translating new laboratory research discoveries into improvements in prostate cancer screening, detection, diagnosis, prevention, and treatment. This competitive renewal proposal contains six new Translational Research Projects, three Core Resources, two Career Development Projects, and two Developmental Research Projects. Project #1 aims to introduce an entirely new imaging/therapy platform featuring the use of tumor-selective promoter driven transgenes;Project #2 hopes to deliver a therapeutic chimeric RNA, featuring an aptamer mediating selective binding to prostate-specific membrane antigen (PSMA) and an siRNA against the DNA-dependent protein kinase, to selectively augment the radiosensitivity of prostate cancer cells;Project #3 plans to exploit the tendency for prostate cancer immune tolerance to become abrogated for a brief period of time following initiation of androgen deprivation therapy as a window for vaccine immunotherapy;Project #4 proposes to follow-up on a successful synthetic lethal functional genomics screen of new molecular drug targets as partners for nucleoside analog DNA methyltransferase inhibitors to deliver treatment combinations to clinical trials for advanced prostate cancer;Project #5 commandeers the tumor-specific homing properties of bone marrow derived mesenchymal stem cells to create a platform for selective delivery and activation of the protoxin PRX302 near prostate cancer cells;Project #6, a population science study, tests the utility of measured telomere lengths in stromal cells and cancer cells in predicting risk for prostate cancer death. These Projects are supported by an Administrative Core, a Pathology/Biospecimen Core, and a Biostatistics/Bioinformatics Core. Finally, the Career Development and Developmental Research Programs, supplemented by $1,000,000 annually from the Patrick C. Walsh Prostate Cancer Research Fund, comprise pipelines of human capital and innovative ideas, respectively, which will fuel future SPORE advances.

Public Health Relevance

This SPORE is dedicated to improving outcomes from prostate cancer, which affects 1 in 5 to 1 in 6 men in the United States, by delivering new approaches to prostate cancer detection, diagnosis, and treatment. Over the planned 5 years of funding, each of these new approaches, as monitored using aggressive milestones/timelines, should move measurably closer to clinical application and benefit.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA058236-19A1
Application #
8739709
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Program Officer
Hruszkewycz, Andrew M
Project Start
1997-09-30
Project End
2019-08-31
Budget Start
2014-09-25
Budget End
2015-08-31
Support Year
19
Fiscal Year
2014
Total Cost
$1,877,328
Indirect Cost
$700,774
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Pradhan, Anjan K; Talukdar, Sarmistha; Bhoopathi, Praveen et al. (2017) mda-7/IL-24 Mediates Cancer Cell-Specific Death via Regulation of miR-221 and the Beclin-1 Axis. Cancer Res 77:949-959
Zamboni, Camila G; Kozielski, Kristen L; Vaughan, Hannah J et al. (2017) Polymeric nanoparticles as cancer-specific DNA delivery vectors to human hepatocellular carcinoma. J Control Release 263:18-28
Sharma, Anup; Mendonca, Janet; Ying, James et al. (2017) The prostate metastasis suppressor gene NDRG1 differentially regulates cell motility and invasion. Mol Oncol 11:655-669
Winchester, Danyelle A; Till, Cathee; Goodman, Phyllis J et al. (2017) Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial. Prostate 77:908-919
Guedes, Liana B; Almutairi, Fawaz; Haffner, Michael C et al. (2017) Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer. Clin Cancer Res 23:4693-4703
Markowski, Mark C; Silberstein, John L; Eshleman, James R et al. (2017) Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol 2017:
Graham, Mindy Kim; Principessa, Lorenzo; Antony, Lizamma et al. (2017) Low p16(INK4a) Expression in Early Passage Human Prostate Basal Epithelial Cells Enables Immortalization by Telomerase Expression Alone. Prostate 77:374-384
Torres, Alba; Alshalalfa, Mohammed; Tomlins, Scott A et al. (2017) Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay. J Mol Diagn 19:475-484
Lotan, Tamara L; Torres, Alba; Zhang, Miao et al. (2017) Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers. Oncotarget 8:22772-22782
Platz, Elizabeth A; Kulac, Ibrahim; Barber, John R et al. (2017) A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts. Cancer Epidemiol Biomarkers Prev 26:1549-1557

Showing the most recent 10 out of 725 publications